Alliance marks Adolescent and Young Adult Cancer Awareness Week
Business Announcement
Updates every hour. Last Updated: 1-Jun-2026 20:15 ET (2-Jun-2026 00:15 GMT/UTC)
Each year, about 85,000 adolescents and young adults (AYA) between the ages of 15 and 39 are diagnosed with cancer in the United States. According to the National Cancer Institute, this represents about 4% of all new cancer diagnoses.
Depending on age and specific diagnosis, many AYA people with cancer may be treated at either a pediatric cancer center or an adult cancer center. However, often these patients don’t feel comfortable in either setting as they feel too old for settings gear toward young children, but too young in centers where most of the patients are elderly.
This population also must navigate challenges surrounding normal milestones for others their age, such as pursuing an education, establishing a career or creating a family. Additionally, financial instability and lack of insurance coverage often deter AYAs from seeking timely medical attention, further complicating their prognosis.
The Alliance for Clinical Trials in Oncology and the Alliance Foundation Trials (AFT) have several active trials specifically poised to help the AYA population as well as others open to people in the AYA demographic.
Medicaid insurance expansions between 2017 and 2023 sharply increased access to medication treatment for opioid use disorder in a period when fatal overdoses continued to climb, according to Rutgers Health researchers.
Their study, published in JAMA Network Open, finds that expanded Medicaid coverage saw meaningful population-level increases in the use of buprenorphine, a medication used to treat opioid use disorder.
Mayo Clinic researchers have developed a new method to identify which proteins are most likely to trigger an immune response — a discovery that could help improve transplant care, regenerative medicine and other areas where the immune system plays a critical role. The results, published in Biomaterials, challenge a common assumption in the field that all proteins are equally likely to provoke immune reactions.
University of Michigan researchers have identified a new target that can suppress tumor growth.
Their findings may lead to new treatment methods for gastroenteropancreatic neuroendocrine tumors.